Skip to search formSkip to main contentSkip to account menu

ixekizumab

National Institutes of Health

Related topics

Related topics

5 relations
1 ML ixekizumab 80 MG/ML Prefilled Syringe1 ML ixekizumab 80 MG/ML Prefilled Syringe [Taltz]

Broader (2)

Antibodies, Monoclonal, HumanizedDermatologic Agents

Narrower (1)

LY2439821

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Comparative 12‐week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real‐world multicenter retrospective study
Today, dermatologists commonly prescribe ustekinumab, secukinumab and ixekizumab in routine clinical practice due to their proven… 
2020
2020
A case of severe psoriasis in a 84‐year‐old women successfully treated with ixekizumab
Dear Editor, Psoriasis is a chronic inflammatory skin disease showing a high impact on quality of life for its aesthetic and… 
2020
2020
Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials.
OBJECTIVES To determine the proportion of patients in Phase 3 studies (SPIRIT-P1 and SPIRIT-P2) who achieved minimal clinically… 
2019
2019
From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management
Interleukin(IL)‐17 inhibitors display higher efficacy than both TNFi and IL‐12/23i, which increased the goal psoriasis area… 
2019
2019
Candida Infections in Clinical Trials of Ixekizumab (Taltz), an Interleukin-17A Monoclonal Antibody, in Patients With Psoriasis or Psoriatic Arthritis
ABSTRACT: Interleukin-17mediates immunity against pathogens such as Candida. Ixekizumab, an anti-interleukin-17A antibody, showed… 
Review
2018
Review
2018
Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review
Dactylitis is a frequent disabling feature of psoriatic arthritis (PsA). Therapeutic strategy on dactylitis is not really… 
2018
2018
SAT0348 Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials
Background Ixekizumab (IXE), a high affinity monoclonal antibody that selectively targets interleukin-17A, has been shown to be… 
2017
2017
OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)
Background Tumour necrosis factor inhibitors (TNF-i) have revolutionised the management of psoriatic arthritis (PsA) yet some… 
2017
2017
SAT0437 Ixekizumab improves nail and skin lesions in patients with active psoriatic arthritis and prior tnf inadequate response
Background Ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting interleukin-17A, significantly improved… 
2017
2017
FRI0503 Validation of new potential targets for remission in psoriatic arthritis in patients treated with golimumab
Background Treat to target recommendations in psoriatic arthritis (PsA) stated that the target of treatment should be remission… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)